{"id":"W4399324721","doi":"10.1200/jco.2024.42.16_suppl.tps1136","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Fulvestrant; Medicine; Internal medicine; Hormone receptor; Oncology; Pharmacology; Cancer; Estrogen receptor; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00234903,0.0007242153,0.004214766,0.0005864342,0.00008144795,0.00004031844,0.0004933448,0.0004242882,0.0003088746],"category_scores_gemma":[0.001012203,0.0004736272,0.0004767337,0.001536034,0.0009553715,0.0008813967,0.0001350344,0.002785426,0.00001069251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219573,"about_ca_system_score_gemma":0.004274024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006620032,"about_ca_topic_score_gemma":0.001252361,"domain_scores_codex":[0.9904431,0.001628277,0.004952944,0.0008614181,0.001342309,0.0007719203],"domain_scores_gemma":[0.9901859,0.003741766,0.00289668,0.0004804803,0.001970357,0.0007248105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3970987,0.03670849,0.01566133,0.0003542182,0.004419593,0.006906529,0.005409337,0.001158777,0.0007837021,0.00003120595,0.0005762244,0.5308919],"study_design_scores_gemma":[0.3272342,0.2629392,0.3765789,0.00629079,0.003547614,0.002447088,0.01059759,0.0005639889,0.0006696534,0.0002793029,0.007689112,0.001162549],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913594,0.001417723,0.000757886,0.002901139,0.0010596,0.002017718,0.0002047151,0.00005645466,0.0002254155],"genre_scores_gemma":[0.9919713,0.001704147,0.004642085,0.0007767497,0.0004666196,0.0001102209,0.00002420928,0.0001366176,0.0001680078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5297294,"threshold_uncertainty_score":0.9997715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03719958490996564,"score_gpt":0.424430612596551,"score_spread":0.3872310276865853,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}